Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France

Pediatric Infectious Disease Journal

Volumn 33, Issue 12, 2014, Pages 1216-1221

  Levy, Corinne ^a,b,c   Varon, Emmanuelle ^d   Picard, Capucine ^e,f,g   Béchet, Stéphane ^b   Martinot, Alain ^a,h   Bonacorsi, Stéphane ^f,i   Cohen, Robert ^a,b,c  

^a GPIP   (France)

^b ACTIV   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Children; Pneumococcal conjugate vaccines; Pneumococcal meningitis

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; VANCOMYCIN; 13-VALENT PNEUMOCOCCAL VACCINE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CULTURE; CHILD; CHILDHOOD MORTALITY; EFFUSION; EMPYEMA; FEMALE; GRAM STAINING; HOSPITALIZATION; HUMAN; HYDROCEPHALUS; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; SEROTYPE; SEX RATIO; STREPTOCOCCUS PNEUMONIAE; SUBDURAL HEMATOMA; VASCULITIS; ADOLESCENT; CLASSIFICATION; EPIDEMIOLOGICAL MONITORING; FRANCE; IMMUNOLOGY; INCIDENCE; INFANT; ISOLATION AND PURIFICATION; MENINGITIS, PNEUMOCOCCAL; NEWBORN; PRESCHOOL CHILD; UTILIZATION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FEMALE; FRANCE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL VACCINES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84926006274     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/inF.0000000000000451     Document Type: Article

References (37)

1. Ben-Shimol S, Greenberg D, Givon-Lavi N, et al.; Israeli Bacteremia and Meningitis Active Surveillance Group. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 2012;30:6600-6607.
2. Black S, France EK, Isaacman D, et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr InfectDis J. 2007;26:771-777.
3. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232-6238.
4. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364:2016-2025.
5. Tin Tin Htar M, Madhava H, Balmer P, et al. A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis. Adv Ther. 2013;30:748-762.
6. Tsai CJ, Griffin MR, Nuorti JP, et al. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis. 2008;46:1664-1672.
7. Feikin DR, Kagucia EW, Loo JD, et al.; Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.
8. Levy C, Varon E, Bingen E, et al.; Bacterial Meningitis Study Group. Pneumococcal meningitis in French children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:168-170.
9. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-256.
10. Hanquet G, Kissling E, Fenoll A, et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis. 2010;16:1428-1439.
11. Levy C, de La Rocque F, Cohen R. Epidemiology of pediatric bacterial meningitis in France. Med Mal Infect. 2009;39:419-31.
12. Haddy RI, Perry K, Chacko CE, et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2005;24:320-323.
13. Saez-Llorens X. Acute bacterial meningitis beyond the neonatal period. Principles and Practice of Pediatric Infectious Diseases Revised Reprint. 2008:284-291.
14. Tacon CL, Flower O. Diagnosis and management of bacterial meningitis in the paediatric population: a review. Emerg Med Int. 2012;2012:320309.
15. Gaudelus J, Cohen R, Hovart J. Evolution of PCV7 coverage in 2006 to 2008: analysis of health records. Medecine et Enfance. 2009; (March): 151-154.
16. Anonymous. French vaccinal calendar recommendations. http://wwwinvssantefr/beh/2010/14-15/beh-14-15pdf. Accessed April 22, 2010.
17. Martinot A, Cohen R, Denis F, et al. Annual trends (2008-2011) in early childhood vaccination coverage for the French population: the Vaccinoscopie (®) study. Arch Pediatr. 2013;20:837-844.
18. Bingen E, Levy C, de la Rocque F, et al.; Bacterial Meningitis Study Group. Bacterial meningitis in children: a French prospective study. Clin Infect Dis. 2005;41:1059-1063.
19. Bingen E, Levy C, Varon E, et al.; Bacterial Meningitis Study Group. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis. 2008;27:191-199.
20. sfm Société Française de Microbiologie. Available at: http://www.sfm-microbiologie.org/UserFiles/file/CASFM/CASFM-2013.pdf. Accessed May 1, 2014.
21. INSTITUT DE VEILLE SANITAIRE. http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Infections-invasives-d-origine-bacterienne-Reseau-EPIBAC/Bulletin-du-reseau-de-surveillance-des-infections-invasives-bacteriennes. Accessed January 1, 2014.
22. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:9127-9131.
23. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203-207.
24. Self WH, Grijalva CG, Zhu Y, et al. Rates of emergency department visits due to pneumonia in the United States, July 2006-June 2009. Acad Emerg Med. 2013;20:957-960.
25. Richter SS, Heilmann KP, Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011 (1.). Emerg Infect Dis. 2013;19:1074-1083.
26. Stockmann C, Ampofo K, Byington CL, et al. Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997-2010 in Utah. Pediatrics. 2013;132:421-28.
27. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125:429-36.
28. Gonzalez BE, Hulten KG, Lamberth L, et al.; U. S. Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J. 2006;25:301-305.
29. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3 pt 1):443-49.
30. Ladhani SN, Andrews NJ, Waight P, et al. Invasive pneumococcal disease, co-morbidities and polysaccharide vaccine use in 5-15 year-old children in England and Wales. Clin Infect Dis. 2013.
31. Ladhani SN, Slack MP, Andrews NJ, et al. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis. 2013;19:61-68.
32. Gil Prieto R, San Román Montero J, Gómez Alejandre C, et al. Epidemiology of pneumococcal meningitis hospitalizations in pediatric population in Spain (1998-2006). Vaccine. 2009;27:2669-2673.
33. Doit C, Barre J, Cohen R, et al. Bactericidal activity against intermediately cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with bacterial meningitis treated with high doses of cefotaxime and vancomycin. Antimicrob Agents Chemother. 1997;41:2050-2052.
34. Pickering L. Red Book: 2003 Report of the Commitee on Infectious Diseases. 26 ed. Elk Grove Village: American Academy of Pediatrics; 2003:293-493.
35. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267-1284.
36. BeCSd G. Observatoire des méningites bactériennes de l'enfant en France. Editorial. Arch Pediatr. 2009;15:S97-S98.
37. Levy C, Varon E, Taha MK, et al. Change in French bacterial meningitis in children resulting from vaccination. Arch Pediatr. 2014;21:736-744.